• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
PVP-K30-----pharma excipients(CAS No.9003-39-8)
Tobramycin
Povidone iodine 20% powder
Povidone iodine 10% powder
SULBACTAM SODIUM STERILE
Food Additives Bulk Sucralose Neotame Advantame Powder

Unichem Labs gets tentative US FDA approval for Sitagliptin Tablets USP

expresspharmaJuly 12, 2021

Tag: Unichem , Januvia , Sitagliptin

Unichem Laboratories has received tentative approval for ANDA of Sitagliptin Tablets USP, 25 mg, 50 mg, and 100 mg from the United States Food and Drug Administration (USFDA) for a generic version of Januvia (sitagliptin) tablets, 25 mg, 50 mg, and 100 mg, of Merck Sharpe and Dohme Corp (Merck).

Sitagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The product will be commercialised from Unichem’s Goa Plant on receipt of full approval.

Previous:Bayer gets US FDA nod for KERENDIA (finerenone) to treat CKD associated with type 2 diabetes

Next:ICMR proposes clinical trial along with Oxford University to evaluate COVID-19 therapy

Related News

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

PharmaSourcesSeptember 19, 2024

InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

PharmaSourcesSeptember 18, 2024

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

PharmaSourcesSeptember 14, 2024

Unichem Labs gets tentative US FDA approval for Sitagliptin Tablets USP | Pharmasources.com

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

Biotech NewswireAugust 28, 2024

Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.

You may like
More>>

Sitagliptin monohydrate

Sitagliptin monohydrate
sitagliptinphosp

sitagliptinphosp
Sitagliptin phosphate CAS 654671-78-0

Sitagliptin phosphate CAS 654671-78-0
Sitagliptin Base

Sitagliptin Base
Sitagliptin Phosphate

Sitagliptin Phosphate
sitagliptin intermediate-5

sitagliptin intermediate-5
98.5% up by HPLC Sitagliptin 486460-32-6

98.5% up by HPLC Sitagliptin 486460-32-6
Sitagliptin Impurity 20 HCl

Sitagliptin Impurity 20 HCl
Sitagliptin EP Impurity A

Sitagliptin EP Impurity A
Sitagliptin phosphate monohydrate

Sitagliptin phosphate monohydrate

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service